Friday 6 May 2016

Acinetobacter spp. bacteraemia

Public Health England has published data relating to resistance to more than one antibiotic among Acinetobacter baumannii and A. lwoffii bacteraemia.

the incidence rate of Acinetobacter spp. bacteraemia has decreased over the eight year period from 2008 to 2015 the country with the highest incidence rate in 2015 was Northern Ireland (1.6 per 100,000 population) within England, the English region with the highest incidence rate was Greater Manchester (1.8 per 100,000 population), while Anglia and Essex had the lowest (1.0/100,000);

Infants have the highest rate of Acinetobacter spp. infection (8.2 per 100,000 population);

Individuals aged 75 years and over also having a relatively high rate (3.7 per 100,000 population), variation is noted by Acinetobacter species in 2015, 50% percent of neonatal Acinetobacter spp. bloodstream infections occurred in infants less than 7 days old (18/36) there were more Acinetobacter spp. reports for females than males with rates of 1.4 and 1.3 per 100,000 population respectively (432 and 381 reports respectively);

Organisms A. lwoffii and A. baumannii continue to be the most common species of Acinetobacter in 2015 from blood isolates (38% and 20% respectively), accounting for over half of all isolates the level of resistance to colistin has fallen to a five year low (2%);

However the proportion of Acinetobacter spp. bacteraemia tested for colistin susceptibility remains below 13% in England, Wales and Northern Ireland in 2015 resistance to a carbapenem (meropenem and/or imipenem) has decreased over the last 5 years a reduction in the proportion of resistant Acinetobacter spp bloodstream isolates was noted between 2011 and 2015 for each of the following antimicrobials: gentamicin, ciprofloxacin, tobramycin and amikacin of 42 isolates of A. baumanii (29) and A. Iwoffi (13) tested, there was no (0%) multidrug resistance to gentamicin, ciprofloxacin, carbapenem and colistin.

The full report can be read here.

 Posted by Dr. Tim Sandle

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers